menu search

RVPH / Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER
Reviva Pharmaceuticals is running a phase 3 study of brilaroxazine in schizophrenia called RECOVER, with results expected in October 2023. A previous phase 2 study showed that brilaroxazine had significant antipsychotic activity, and a potentially differentiated side effect profile versus Abilify. RVPH had $11.2M in cash and cash equivalents at the end of Q2'23, and could fall heavily if the phase 3 study doesn't succeed. Read More
Posted: Sep 27 2023, 02:48
Author Name: Seeking Alpha
Views: 092074

RVPH News  

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

By Seeking Alpha
November 2, 2023

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo o more_horizontal

Reviva Pharma's schizophrenia drug succeeds in late-stage study

By Reuters
October 30, 2023

Reviva Pharma's schizophrenia drug succeeds in late-stage study

Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study. more_horizontal

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

By Seeking Alpha
September 27, 2023

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

Reviva Pharmaceuticals is running a phase 3 study of brilaroxazine in schizophrenia called RECOVER, with results expected in October 2023. A previous more_horizontal

Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference

By GlobeNewsWire
March 7, 2023

Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference

CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clin more_horizontal

Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

By GlobeNewsWire
September 7, 2022

Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CUPERTINO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clin more_horizontal


Search within

Pages Search Results: